Majalah Kardiologi Indonesia最新文献

筛选
英文 中文
Break the chain of COVID-19 transmission: Perspective from a cardiologist-in-practice 打破COVID-19传播链:来自在职心脏病专家的观点
Majalah Kardiologi Indonesia Pub Date : 2020-05-20 DOI: 10.30701/IJC.1000
S. Purwowiyoto, B. Purwowiyoto
{"title":"Break the chain of COVID-19 transmission: Perspective from a cardiologist-in-practice","authors":"S. Purwowiyoto, B. Purwowiyoto","doi":"10.30701/IJC.1000","DOIUrl":"https://doi.org/10.30701/IJC.1000","url":null,"abstract":"Indonesia is currently suffering through a pandemic outbreak of severe respiratory syndrome Coronavirus 2 (SARS-CoV-2) known as Coronavirus Disease 2019 (COVID-19). Every day this infection raises double health community is fighting COVID-19 with their armamentarium and policy. Indonesian Heart Association (IHA) has already issued the statement about cardiovascular services during the outbreak of COVID-19. The policy is rescheduling non urgent outpatient visits as necessary social distancing strategy in outpatient clinic and using personal protective equipment (PPE) in outpatient clinic or during the cardiac examination (echocardiography cardiac CT electrophysiology and invasive cardiology). Most of international recommendations have recommended social distancing and reschedule non urgent visits. This document gives a general information about the prevention of COVID-19 in cardiology department.","PeriodicalId":32916,"journal":{"name":"Majalah Kardiologi Indonesia","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48994767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Recommendations of RAAS Blocker Use Amidst The Coronavirus Pandemic 冠状病毒大流行期间RAAS阻滞剂的使用建议
Majalah Kardiologi Indonesia Pub Date : 2020-05-20 DOI: 10.30701/ijc.v1i1.1007
J. Henrina, I. C. S. Putra, H. Gunawan, I. Cahyadi, L. Suciadi
{"title":"Recommendations of RAAS Blocker Use Amidst The Coronavirus Pandemic","authors":"J. Henrina, I. C. S. Putra, H. Gunawan, I. Cahyadi, L. Suciadi","doi":"10.30701/ijc.v1i1.1007","DOIUrl":"https://doi.org/10.30701/ijc.v1i1.1007","url":null,"abstract":"With a rapidly growing pandemic of coronavirus disease of 2019 (COVID-19), a public health emergency of international concern, the medical communities and national health systems are being tested for their preparedness. The culprit that is responsible for this viral respiratory disease, is a novel type of coronavirus, now identified as severe acute respiratory syndrome coronavirus - 2 (SARS-CoV2). At the present time, there are gaps in the knowledge regarding the safety of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for COVID-19 patients due to concern of ACE2, which is critical for viral entry and their levels are upregulated when using these (Renin Angiotensin Aldosterone System) RAAS blockers. ACE2 is a glycoprotein metalloprotease that plays an essential role in physiologic and pathological states and it is ubiquitously found in human organs. Despite sharing homology, ACE is different from ACE2, and while the former cleaves angiotensin 1 to angiotensin 2, the latter cleaves angiotensin two to angiotensin 1-7. Extrapolated from experimental animal studies, ACE2 and angiotensin 1-7 are important and protective for the lung physiology based on mice model of acute lung injury by various causes. Other evidence also demonstrates harm over benefits when stopping RAAS blockers, particularly in patients with cardiovascular disease, in which using these drugs are proven to be life-saving. In the light of the paucity of evidence derived from well-designed study, societies and colleges recommend continuing RAAS blockers until new evidence says otherwise.","PeriodicalId":32916,"journal":{"name":"Majalah Kardiologi Indonesia","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43981331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Break the chain of COVID-19 transmission: Cardiologist Perspective 打破COVID-19传播链:心脏病专家的观点
Majalah Kardiologi Indonesia Pub Date : 2020-05-20 DOI: 10.30701/ijc.v1i1.1000
S. Purwowiyoto, B. Purwowiyoto
{"title":"Break the chain of COVID-19 transmission: Cardiologist Perspective","authors":"S. Purwowiyoto, B. Purwowiyoto","doi":"10.30701/ijc.v1i1.1000","DOIUrl":"https://doi.org/10.30701/ijc.v1i1.1000","url":null,"abstract":"Indonesia is currently suffering through a pandemic outbreak of severe respiratory syndrome coronavirus 2 (SARS-CoV-2) known as Coronavirus Disease 2019 (COVID-19). Every day this infection raises double, health community is fighting COVID-19 with their armamentarium and policy. Indonesian Heart Association (IHA) has already issued the statement about cardiovascular services during the outbreak of COVID-19. The policy is rescheduling non urgent outpatient visits as necessary, social distancing strategy in outpatient clinic and using personal protective equipment (PPE) in outpatient clinic or during the cardiac examination (echocardiography, cardiac CT, electrophysiology and invasive cardiology). Most of international recommendations have recommended social distancing and reschedule non urgent visits. This document gives a general information about the prevention of COVID-19 in cardiology department.","PeriodicalId":32916,"journal":{"name":"Majalah Kardiologi Indonesia","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44694120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Managing QT prolongation in the Era of Coronavirus Disease 2019 (COVID-19) 2019冠状病毒病(COVID-19)时期QT间期延长的管理
Majalah Kardiologi Indonesia Pub Date : 2020-05-20 DOI: 10.30701/ijc.v1i1.1002
S. Purwowiyoto, D. Hermanto, M. Iqbal
{"title":"Managing QT prolongation in the Era of Coronavirus Disease 2019 (COVID-19)","authors":"S. Purwowiyoto, D. Hermanto, M. Iqbal","doi":"10.30701/ijc.v1i1.1002","DOIUrl":"https://doi.org/10.30701/ijc.v1i1.1002","url":null,"abstract":"Indonesia has declared a COVID-19 outbreaks because of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in March 2020. COVID-19 has significantly increased morbidity and mortality worldwide. Some studies have shown good clinical outcomes with the use of combination of chloroquine or hydroxychloroquine and azithromycin. That drugs can prolong the QT interval and increase the risk of Torsade de Pointes (TdP). The risk is increasing in several conditions such as in critical patients, metabolic disorders, sepsis, multiorgan dysfunction and with drug-drug interactions. Cardiologists need to know how to manage this condition to reduce the risk of TdP.","PeriodicalId":32916,"journal":{"name":"Majalah Kardiologi Indonesia","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41373526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
How to manage QT prolongation in COVID-19 patients 如何处理COVID-19患者QT间期延长
Majalah Kardiologi Indonesia Pub Date : 2020-05-20 DOI: 10.30701/IJC.1002
S. Purwowiyoto, D. Hermanto, M. Iqbal
{"title":"How to manage QT prolongation in COVID-19 patients","authors":"S. Purwowiyoto, D. Hermanto, M. Iqbal","doi":"10.30701/IJC.1002","DOIUrl":"https://doi.org/10.30701/IJC.1002","url":null,"abstract":"Indonesia has declared a COVID-19 outbreaks because of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) in March 2020. COVID-19 has significantly increased morbidity and mortality worldwide. Some studies have shown good clinical outcomes with the use of combination of chloroquine or hydroxychloroquine and azithromycin. That drugs can prolong the QT interval and increase the risk of Torsade de Pointes (TdP). The risk is increasing in several conditions such as in critical patients’ metabolic disorders sepsis multiorgan dysfunction and with drug-drug interactions. Cardiologists need to know how to manage this condition to reduce the risk of TdP.","PeriodicalId":32916,"journal":{"name":"Majalah Kardiologi Indonesia","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46755221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
High-grade Atrioventricular Block in Pilot 重度房室传导阻滞
Majalah Kardiologi Indonesia Pub Date : 2020-05-20 DOI: 10.30701/ijc.v1i1.950
S. Salim, S. Raharjo, D. Hermanto, D. Hanafy, Y. Yuniadi
{"title":"High-grade Atrioventricular Block in Pilot","authors":"S. Salim, S. Raharjo, D. Hermanto, D. Hanafy, Y. Yuniadi","doi":"10.30701/ijc.v1i1.950","DOIUrl":"https://doi.org/10.30701/ijc.v1i1.950","url":null,"abstract":"Background: Atrioventricular (AV) block is a threatening condition that caused sudden loss of consciousness and death, notably if happened to aircraft pilot will compromise the reliability of flight operations and safety. Cardiac arrhythmia is well known as one of the main disqualifier for loss of flying license, and discriminating between benign and potentially significant rhythm abnormalities remains a challenge. The present case describes the electrophysiological feature of a high-grade AV block in an aircraft pilot. \u0000Case illustration: A 60-year-old male worked as commercial aircraft pilot presented with asymptomatic high-grade AV block during inflight Holter monitoring. He had never experienced any remarkable symptoms nor history of near syncope, but had a history of percutaneous coronary intervention (PCI) with one stent at left circumflex (LCx) coronary artery. Electrophysiology (EP) study revealed AH interval of 105 ms, HV interval of 50 ms, AV node effective refractory period of 280 ms and Weckenbach point of 330 ms, suggesting a normal EP study. Stimulation with atrial pacing and ATP showed prolongation of AH interval without changes in HV interval, showing the presence of a supra-Hisian AV node dysfunction. The highly demanding physiological environment in aircraft elucidate the likelihood of vagotonic cause of his condition and pacemaker implantation was not warranted. \u0000Conclusion: Atrioventricular (AV) block is an AV conduction disorder that can manifests in various symptoms and severity. Electrophysiology study is considered as a modality to locate the site of block that allows the avoidance of unnecessary permanent pacing and the appropriate prophylactic pacing.","PeriodicalId":32916,"journal":{"name":"Majalah Kardiologi Indonesia","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44302848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transient ischemic dilation as a diagnostic marker in myocardial perfusion SPECT protocols: a systematic review and meta-analysis 短暂性脑缺血扩张作为心肌灌注SPECT诊断指标:系统回顾和荟萃分析
Majalah Kardiologi Indonesia Pub Date : 2020-05-19 DOI: 10.30701/ijc.v0i0.981
N. Namiranian, M. Emami, A. Naghedi, S. Razavi-Ratki
{"title":"Transient ischemic dilation as a diagnostic marker in myocardial perfusion SPECT protocols: a systematic review and meta-analysis","authors":"N. Namiranian, M. Emami, A. Naghedi, S. Razavi-Ratki","doi":"10.30701/ijc.v0i0.981","DOIUrl":"https://doi.org/10.30701/ijc.v0i0.981","url":null,"abstract":"Abstract \u0000Background: Transient ischemic dilation (TID) measures left ventricle (LV) volume changes which can be associated with combination of myocardial and endocardial ischemia. Various stress methods, single photon emission computerized tomography (SPECT) imaging protocol, camera and software incite controversy on TID cut off. The purpose of this study was to evaluate the TID ratio in detection of coronary artery disease (CAD) categories in a systematic review and meta-analysis. Method: We conducted a systematic search of electronic databases (PubMed, Scopus, Embase and Web of Science) up to 1 January 2017. The reference lists of all included studies were searched for a higher accuracy. The search strategy was according a defined PICO as P: none, I: Transient ischemic dilation, O: Coronary Artery Diseases, C: Angiographies. Statistical analysis was done by Comprehensive meta-analysis software version 2 (CMA-2). \u0000Result: After study selection process, 7 studies were selected for data extraction. TID was studied from 1987. The sample size of included studies ranged between 86 and 545. The mean age of included patients varied between 58 and 69 years old. Ranges of TID in CAD categories were excluded. The pooled estimates of TID in single and dual pharmacological stress test in three CAD categories were calculated. \u0000Conclusion: Our findings show that more studies are needed to compare the TID variability. Although in this study meta-analysis was done and TID was summarized from studies but the software differences were ignored.","PeriodicalId":32916,"journal":{"name":"Majalah Kardiologi Indonesia","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46152011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perlukah kriteria hipertensi baru dan target pengendalian tekanan darah yang lebih agresif? Telaah paska studi SPRINT serta panduan ACC/AHA 2017 dan ESH/ESC 2018 需要一个新的高血压标准和一个更积极的血压控制目标吗?已完成SPRINT研究和ACC/AHA 2017和ESH/ESC 2018
Majalah Kardiologi Indonesia Pub Date : 2019-09-11 DOI: 10.30701/ijc.v39i2.765
Bambang Widyantoro
{"title":"Perlukah kriteria hipertensi baru dan target pengendalian tekanan darah yang lebih agresif? Telaah paska studi SPRINT serta panduan ACC/AHA 2017 dan ESH/ESC 2018","authors":"Bambang Widyantoro","doi":"10.30701/ijc.v39i2.765","DOIUrl":"https://doi.org/10.30701/ijc.v39i2.765","url":null,"abstract":"","PeriodicalId":32916,"journal":{"name":"Majalah Kardiologi Indonesia","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48556400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
EFFECTS OF N-ACETYLCYSTEIN ON HSCRP LEVEL IN ACUTE MYOCARDIAL INFARCTION PATIENTS RECEIVING FIBRINOLYTIC THERAPY n -乙酰半胱氨酸对接受纤溶治疗的急性心肌梗死患者HSCRP水平的影响
Majalah Kardiologi Indonesia Pub Date : 2019-09-11 DOI: 10.30701/ijc.v39i4.798
S. Indriani, A. Yasa', T. Wasyanto
{"title":"EFFECTS OF N-ACETYLCYSTEIN ON HSCRP LEVEL IN ACUTE MYOCARDIAL INFARCTION PATIENTS RECEIVING FIBRINOLYTIC THERAPY","authors":"S. Indriani, A. Yasa', T. Wasyanto","doi":"10.30701/ijc.v39i4.798","DOIUrl":"https://doi.org/10.30701/ijc.v39i4.798","url":null,"abstract":"EFFECTS OF N-ACETYLCYSTEIN ON HSCRP LEVEL IN ACUTE MYOCARDIAL  INFARCTION  PATIENTS RECEIVING FIBRINOLYTIC THERAPY \u0000  \u0000Savithri Indriani1, Ahmad Yasa1, Trisulo Wasyanto1 \u00001Department of Cardiology and Vascular Medicine, Faculty of Medicine, \u0000Universitas Sebelas Maret, RS Dr. Moewardi, Surakarta, Indonesia \u0000  \u0000Background: Worldwide, coronary heart disease (CHD) is a leading cause of death. Inflammation in CHD and acute myocardial infarction (AMI) is a trigger due to the formation of atheroma plaques in the coronary arteries. N-Acetylcysteine ​​(NAC) can prevent inflammation, remodeling and left ventricular dysfunction, interstitial fibrosis, and improve survival. \u0000Objective: To determine the effect of NAC on hsCRP levels in patients with acute myocardial infarction who received fibrinolytic therapy. \u0000Methods: This study was an experimental study with pre and post, single blind and randomization methods on the effect of NAC on hsCRP levels compared to controls carried out in July - August 2018 on the incidence of ST Elevation Myocardial Infarction (STEMI) came to Dr Moewardi Hospital and get fibrinolytic therapy. \u0000Results: A total of 33 patients were included in this study, there were 15 patients (mean age 58.80 ± 8.54 years) of the control group and 18 patients (mean age 55.45 ± 9.92 years) the treatment group receiving additional therapy of NAC evervescent 600 mg three times a day for three days . This study showed that hsCRP levels after intervention in the control and treatment groups were significantly different with p = 0.001. The level of hsCRP in the control group after administration of NAC had a median of 114.50 mg / L (18.60 - 300.00) while in the treatment group had a median of 18.75 mg / L (5.50 - 102.90). \u0000Conclusion: The addition of NAC 600 mg of therapy three times daily for 3 days can reduce hsCRP levels in patients with STEMI receiving fibrinolytic therapy compared to patients with acute myocardial infarction with ST segment elevation who did not receive additional NAC therapy. \u0000Keywords: hsCRP, N-Acetylcysteine, acute myocardial infarction \u0000. \u0000  \u0000PENGARUH N-ACETYLCYSTEIN TERHADAP HSCRP PADA PASIEN INFARK MIOKARD AKUT DENGAN ELEVASI SEGMEN ST YANG MENDAPAT TERAPI FIBRINOLITIK \u0000  \u0000Savithri Indriani1, Ahmad Yasa1, Trisulo Wasyanto1 \u0000Departemen Ilmu Penyakit Jantung dan Pembuluh Darah, Fakultas Kedokteran \u0000Universitas Sebelas Maret, RS Dr. Moewardi, Surakarta, Indonesia \u0000  \u0000Latar Belakang: Di seluruh dunia, penyakit jantung koroner (PJK) merupakan penyebab utama kematian. Inflamasi pada PJK dan infark miokard akut (IMA) merupakan pemicu akibat terbentuknya plak ateroma pada arteri koroner. N-Acetylcysteine (NAC) dapat mencegah inflamasi, remodeling dan disfungsi ventrikel kiri, fibrosis interstisial, dan meningkatkan survival. \u0000Tujuan: Untuk mengetahui pengaruh  NAC terhadap kadar hsCRP pada pasien infark miokard akut yang mendapatkan terapi fibrinolitik. \u0000Metode:  Penelitian ini merupakan penelitian eksperimental dengan metode pre d","PeriodicalId":32916,"journal":{"name":"Majalah Kardiologi Indonesia","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47686046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Left Atrial Thrombus Resolution Using Unfractionated Heparin and Warfarin in a Patient with Mitral Stenosis 应用未分级肝素和华法林治疗二尖瓣狭窄患者左心房血栓
Majalah Kardiologi Indonesia Pub Date : 2019-09-11 DOI: 10.30701/ijc.v40i3.870
Z. Zainuddin, Endang Ratnaningsiah, Andika Rizki Lubis, Sebastian Andi Manurung, T. Pratikto, A. Soesanto
{"title":"Left Atrial Thrombus Resolution Using Unfractionated Heparin and Warfarin in a Patient with Mitral Stenosis","authors":"Z. Zainuddin, Endang Ratnaningsiah, Andika Rizki Lubis, Sebastian Andi Manurung, T. Pratikto, A. Soesanto","doi":"10.30701/ijc.v40i3.870","DOIUrl":"https://doi.org/10.30701/ijc.v40i3.870","url":null,"abstract":"Abstract \u0000Background:  Though the use of Low Molecular Weight Heparin (LMWH) in general is preferred due to its convenient and eliminates the need for activated Partial Thromboplastin Time ( aPTT) monitoring but Unfractionated Heparin (UFH) is still widely used in clinical setting due to its availability and low price. Besides UFH, the use of oral anticoagulant therapy with warfarin, has been the standard therapy for the prevention of thromboembolism in patients with AF. Our aim is to report a case of the resolution of left atrial thrombus in a patient with mitral stenosis. \u0000Case Illustration:  A Case report of a female patient aged 54 years who admitted with a sudden neurological deficits and mitral stenosis with atrial fibrillation.  Transthoracal Echocardiography (TTE) showed mobile thrombus which moved and obstructed the mitral valve during diastolic phase. Unfractionated heparin (UFH) was administered 3000 unit bolus intravenously and maintained with 600 unit per hour with the combination of warfarin 2 mg for five days. TTE evaluation showed the resolution of LA thrombus.  \u0000Conclusion : The administration of the combination of UFH and warfarin had successfully caused  resolution of  the LA thrombus and prevented the patient from surgical intervention. This case report indicated that Unfractionated Heparin and Warfarin were still the treatments option in LA thrombus patients with mitral stenosis and atrial fibrillation. \u0000  \u0000Key words :Left atrial thrombus, unfractionated heparin, thrombus resolution \u0000  \u0000 ","PeriodicalId":32916,"journal":{"name":"Majalah Kardiologi Indonesia","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44401576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信